MedPath

Phase II study of Neoadjuvant Letrozole for Postmenopausal Women with Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-06)

Phase 2
Conditions
Postmenopausal, hormone-receptor positive and primary breast cancer
Registration Number
JPRN-UMIN000001325
Lead Sponsor
Japan Breast Cancer Research Group (JBCRG)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
0
Inclusion Criteria

Not provided

Exclusion Criteria

1. Unmanageable serious complications 2. HCV 3. Unmanageable diabetes 4. Suspicious infection with fever 5. Active double cancer 6. Inflammatory breast cancer 7. Bilateral breast cancer 8. 10. History of drug-hypersensitivity 9. Receiving continuous systematic steroids, estrogen and Raloxifene 10. Mental disease 11. Patient judged inappropriate for this study by the physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Secondary Outcome Measures
NameTimeMethod
Pathological CR rate, Breast Conserving Surgery rate, Safety, Disease- free survival and Overall survival
© Copyright 2025. All Rights Reserved by MedPath